Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Arecor Therapeutics PLC ( (GB:AREC) ) has provided an announcement.
Arecor Therapeutics reported audited full-year 2025 results highlighting strong operational progress in its diabetes and oral peptide delivery franchises, despite lower revenue stemming from the closure of Tetris Pharma. Lead insulin candidate AT278 advanced toward Phase 2, supported by positive U.S. FDA feedback, a co-development deal with Sequel Med Tech to integrate AT278 into the twiist automated insulin delivery system, and post-year-end confirmation of the parties’ intent to broaden this into a full co-development and commercialisation partnership.
The group also advanced its early-stage oral peptide delivery platform, filed new international patents to bolster intellectual property, and signed three new Arestat-based formulation collaborations worth over £1 million in pre-license revenue. Financially, Arecor strengthened its balance sheet via an $11 million royalty financing with Ligand Pharmaceuticals and ended the year with £6.1 million in cash, giving it runway to complete Phase 2 trial-enabling work for AT278 and build a data package for its oral peptide technology while maintaining tight cost control.
Spark’s Take on AREC Stock
According to Spark, TipRanks’ AI Analyst, AREC is a Neutral.
Arecor Therapeutics’ score is driven by positive corporate events, including strategic partnerships and IP expansion, which bolster its market position. However, financial performance challenges, such as ongoing losses and cash flow issues, weigh heavily on the overall score. Technical analysis and valuation present a neutral outlook, reflecting the typical risks and opportunities in the biotech sector.
To see Spark’s full report on AREC stock, click here.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a Cambridge, UK-based clinical-stage biotech company focused on developing superior therapeutics for diabetes, obesity and other cardiometabolic diseases. Its lead asset, AT278, is the only ultra-concentrated (500U/mL), ultra-rapid-acting insulin in development, and the company is also building a novel oral peptide delivery platform, initially targeting GLP-1 receptor agonists for a multi-billion-dollar market.
Average Trading Volume: 12,776
Technical Sentiment Signal: Sell
Current Market Cap: £24.35M
For an in-depth examination of AREC stock, go to TipRanks’ Overview page.